PTC Therapeutics Inc
PTCT78.570USD
+3.980+5.34%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
6.28BMarket Cap
7.81P/E TTM
More Details of PTC Therapeutics Inc Company
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
PTC Therapeutics Inc Info
Ticker SymbolPTCT
Company namePTC Therapeutics Inc
IPO dateJun 20, 2013
CEOKlein (Matthew B)
Number of employees939
Security typeOrdinary Share
Fiscal year-endJun 20
Address500 Warren Corporate Center Drive
CityWARREN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code07059
Phone19082227000
Websitehttps://www.ptcbio.com/
Ticker SymbolPTCT
IPO dateJun 20, 2013
CEOKlein (Matthew B)
Company Executives of PTC Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Matthew B. Klein, M.D.
Dr. Matthew B. Klein, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
164.14K
+8.03%
Mr. Michael Schmertzler
Mr. Michael Schmertzler
Independent Chairman of the Board
Independent Chairman of the Board
126.60K
+0.53%
Mr. Mark Elliott Boulding
Mr. Mark Elliott Boulding
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
60.20K
--
Ms. Christine Marie Utter
Ms. Christine Marie Utter
Senior Vice President, Chief Accounting Officer, Head - People Services
Senior Vice President, Chief Accounting Officer, Head - People Services
54.45K
-3.13%
Mr. Eric Pauwels
Mr. Eric Pauwels
Chief Business Officer
Chief Business Officer
19.79K
--
Mr. Pierre Gravier
Mr. Pierre Gravier
Chief Financial Officer
Chief Financial Officer
18.36K
-12.05%
Mr. David P. Southwell
Mr. David P. Southwell
Independent Director
Independent Director
16.17K
--
Dr. Jerome B. Zeldis, M.D., Ph.D.
Dr. Jerome B. Zeldis, M.D., Ph.D.
Independent Director
Independent Director
16.17K
+2.10%
Ms. Stephanie S. Okey
Ms. Stephanie S. Okey
Independent Director
Independent Director
5.67K
-13.27%
Ms. Emma Reeve
Ms. Emma Reeve
Independent Director
Independent Director
4.33K
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Matthew B. Klein, M.D.
Dr. Matthew B. Klein, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
164.14K
+8.03%
Mr. Michael Schmertzler
Mr. Michael Schmertzler
Independent Chairman of the Board
Independent Chairman of the Board
126.60K
+0.53%
Mr. Mark Elliott Boulding
Mr. Mark Elliott Boulding
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
60.20K
--
Ms. Christine Marie Utter
Ms. Christine Marie Utter
Senior Vice President, Chief Accounting Officer, Head - People Services
Senior Vice President, Chief Accounting Officer, Head - People Services
54.45K
-3.13%
Mr. Eric Pauwels
Mr. Eric Pauwels
Chief Business Officer
Chief Business Officer
19.79K
--
Mr. Pierre Gravier
Mr. Pierre Gravier
Chief Financial Officer
Chief Financial Officer
18.36K
-12.05%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
413.04M
51.20%
Non-US
393.74M
48.80%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.30%
RTW Investments L.P.
9.65%
BlackRock Institutional Trust Company, N.A.
7.08%
Wellington Management Company, LLP
6.13%
Janus Henderson Investors
4.70%
Other
62.14%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.30%
RTW Investments L.P.
9.65%
BlackRock Institutional Trust Company, N.A.
7.08%
Wellington Management Company, LLP
6.13%
Janus Henderson Investors
4.70%
Other
62.14%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
42.03%
Investment Advisor
33.83%
Hedge Fund
18.76%
Research Firm
9.30%
Corporation
1.73%
Individual Investor
0.82%
Bank and Trust
0.60%
Pension Fund
0.45%
Venture Capital
0.24%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
550
79.92M
99.54%
-10.07M
2025Q2
548
83.85M
105.78%
-6.53M
2025Q1
551
82.28M
103.88%
-8.58M
2024Q4
513
80.63M
102.26%
-7.88M
2024Q3
503
82.04M
106.59%
-9.34M
2024Q2
498
82.97M
107.86%
-13.36M
2024Q1
493
89.17M
116.42%
-6.48M
2023Q4
485
88.17M
116.52%
-2.91M
2023Q3
477
85.04M
112.75%
-2.96M
2023Q2
478
84.63M
112.42%
-161.84K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
8.83M
11.11%
+236.45K
+2.75%
Jun 30, 2025
RTW Investments L.P.
7.75M
9.75%
+263.29K
+3.52%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.79M
7.29%
-157.94K
-2.66%
Jun 30, 2025
Wellington Management Company, LLP
4.69M
5.91%
-725.03K
-13.38%
Jun 30, 2025
Janus Henderson Investors
3.18M
4%
+258.29K
+8.86%
Jun 30, 2025
Armistice Capital LLC
4.74M
5.96%
-699.38K
-12.87%
Jun 30, 2025
TD Securities, Inc.
2.45M
3.08%
-167.24K
-6.40%
Jun 30, 2025
State Street Investment Management (US)
3.00M
3.77%
+541.56K
+22.06%
Jun 30, 2025
D. E. Shaw & Co., L.P.
2.44M
3.07%
+992.42K
+68.67%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.93M
2.44%
+60.71K
+3.24%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Neuroscience and Healthcare ETF
4.62%
Invesco Biotechnology & Genome ETF
3.67%
Harbor Human Capital Factor US Small Cap ETF
2.39%
ALPS Medical Breakthroughs ETF
2.18%
Virtus LifeSci Biotech Products ETF
2.14%
Euclidean Fundamental Value ETF
2.13%
First Trust NASDAQ Pharmaceuticals ETF
1.89%
Global X Guru Index ETF
1.68%
State Street SPDR S&P Biotech ETF
1.68%
Invesco Dorsey Wright Healthcare Momentum ETF
1.64%
View more
iShares Neuroscience and Healthcare ETF
Proportion4.62%
Invesco Biotechnology & Genome ETF
Proportion3.67%
Harbor Human Capital Factor US Small Cap ETF
Proportion2.39%
ALPS Medical Breakthroughs ETF
Proportion2.18%
Virtus LifeSci Biotech Products ETF
Proportion2.14%
Euclidean Fundamental Value ETF
Proportion2.13%
First Trust NASDAQ Pharmaceuticals ETF
Proportion1.89%
Global X Guru Index ETF
Proportion1.68%
State Street SPDR S&P Biotech ETF
Proportion1.68%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion1.64%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of PTC Therapeutics Inc?
The top five shareholders of PTC Therapeutics Inc are:
The Vanguard Group, Inc. holds 8.83M shares, accounting for 11.11% of the total shares.
RTW Investments L.P. holds 7.75M shares, accounting for 9.75% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 5.79M shares, accounting for 7.29% of the total shares.
Wellington Management Company, LLP holds 4.69M shares, accounting for 5.91% of the total shares.
Janus Henderson Investors holds 3.18M shares, accounting for 4.00% of the total shares.
The Vanguard Group, Inc. holds 8.83M shares, accounting for 11.11% of the total shares.
RTW Investments L.P. holds 7.75M shares, accounting for 9.75% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 5.79M shares, accounting for 7.29% of the total shares.
Wellington Management Company, LLP holds 4.69M shares, accounting for 5.91% of the total shares.
Janus Henderson Investors holds 3.18M shares, accounting for 4.00% of the total shares.
What are the top three shareholder types of PTC Therapeutics Inc?
The top three shareholder types of PTC Therapeutics Inc are:
The Vanguard Group, Inc.
RTW Investments L.P.
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
RTW Investments L.P.
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of PTC Therapeutics Inc (PTCT)?
As of 2025Q3, 550 institutions hold shares of PTC Therapeutics Inc, with a combined market value of approximately 79.92M, accounting for 99.54% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -6.24%.
What is the biggest source of revenue for PTC Therapeutics Inc?
In FY2024, the -- business generated the highest revenue for PTC Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
